As the first therapeutically interchangeable Humira-referenced biosimilar Cyltezo may gain a distinct marketing advantage over competitors.
As the first therapeutically interchangeable Humira-referenced biosimilar Cyltezo may gain a distinct marketing advantage over competitors.